Reuters logo
Insmed's lung infection drug fails mid-stage study
March 26, 2014 / 11:16 AM / in 4 years

Insmed's lung infection drug fails mid-stage study

March 26 (Reuters) - Insmed Inc said its only experimental drug failed to meet the main goal of a mid-stage trial on patients with a form of bacterial lung infection.

The company said the drug, Arikayce, did not reduce bacterial density, a measure of change in infection, in patients with nontuberculous mycobacterial lung infections.

The trial compared the drug, in combination with a standard treatment, to a combination of placebo and the standard treatment. (Reporting By Vrinda Manocha in Bangalore; Editing by Savio D‘Souza)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below